- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.06. | ADA: Novo's Lange says 'jury still out' on CagriSema amid tough retatrutide comparisons | ||
| 10.06. | Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen's Tepezza | ||
| 10.06. | Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B | ||
| 10.06. | Cancer-focused Parabilis' upsized $670M IPO breaks new for record for biotechs | ||
| 10.06. | Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue | ||
| 09.06. | Fueled by M&A and partnerships, biotech is poised for continued growth: EY | ||
| 09.06. | Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M | ||
| 09.06. | Lilly moves deeper into Alzheimer's research with AlzeCure licensing deal | ||
| 09.06. | ADA: AstraZeneca's oral GLP-1 shows 'competitive efficacy' in phase 2, setting stage for pivotal program | ||
| 09.06. | Bial bails after Parkinson's fail, axing asset over phase 2 miss | ||
| 09.06. | GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer | ||
| 08.06. | City aims to lay foundation for RNAi renaissance with nearly $100M series B | ||
| 08.06. | Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger | ||
| 08.06. | J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio | ||
| 08.06. | Incyte inks $2B deal to add Star unit to late-phase constellation and challenge Takeda | ||
| 08.06. | GSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regression | ||
| 08.06. | Roche bets $700M upfront on Nurix's late-phase BTK degrader to tee up Lilly showdown | ||
| 06.06. | ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes | ||
| 06.06. | ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy | ||
| 05.06. | Affibody gets izokibep 'back on track' while seeking 'new home' after drug's Acelyrin rejection | ||
| 04.06. | Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 | ||
| 04.06. | As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too | ||
| 04.06. | Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 | ||
| 04.06. | From business strategy to CAR-T responses, for Cabaletta it's all about 'durability' | ||
| 04.06. | Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.